Hidden Pocket in Human Bitter Taste Receptor Discovered
en-GBde-DEes-ESfr-FR

Hidden Pocket in Human Bitter Taste Receptor Discovered


“Tasting Upside-Down - An Unusual Sensing Mechanism was Found in Human Bitter Sensing” A new study revealed that some bitter molecules target their sensor through binding simultaneously at two distinct locations, one outside the cell, and the other inside it. This discovery is fascinating because bitter taste receptors are expressed in extra-oral tissues and the new study shows the potential of our cells to sense not only external but also internal signals, opening up new possibilities for drug design, including asthma and inflammation.

Link to pictures: https://drive.google.com/drive/folders/1LJDhHEGZVFO1O57_sUnyqURoYt5cBQfT?usp=drive_link

A new study, published in Nature Communications, led by Prof. Masha Niv from the Hebrew University of Jerusalem, Dr. Moran Shalev-Benami from the Weizmann Institute, and Dr. Dorothee Weikert from FAU Erlangen, describes an exciting discovery that changes the way we understand human bitter taste receptors. The research has revealed a hidden "pocket" inside one of the body’s bitter taste receptors, called TAS2R14. This breakthrough could help not only understand how our tongue senses bitterness, but also investigate the physiological roles of bitter taste receptors that are expressed extraorally.

There are many chemically different molecules that trigger bitter taste sensations, and the body uses a family of 25 receptors to detect them. Interestingly, many drugs also activate this bitter taste system.

Unlike most other bitter taste receptors, TAS2R14 is highly "promiscuous," meaning it can recognize and respond to a wide variety of bitter substances, from vitamins to certain drugs and even odorants. The receptor’s ability to respond to such a diverse array of compounds makes it a subject of great interest for researchers. Until now, however, how exactly TAS2R14 binds to these compounds and triggers a response in the body was not fully understood.

The scientists used an advanced technology in electron microscopy (EM) that allows to see the three-dimensional architecture of proteins in great detail. This technique, called cryo-EM, enabled to solve the structure of TAS2R14 together with flufenamic acid (FFA)—a bitter anti-inflammatory drug that activates TAS2R14. The structure led to a surprising discovery: the drug binds simultaneously at two distinct positions of the receptor: one copy bound at an extracellular site and the other at the intracellular one. This dual binding, sheds new light on how the receptor interacts with diverse chemical compounds, including those that cause bitterness.

“This discovery gives us a new clue into how TAS2R14 works,” explained Professor Niv. “It’s fascinating because the receptor is not just sensing chemicals from outside the cell, like food or drugs, but also 'tasting' what’s happening inside the cell. This new intracellular pocket could be a game-changer in how we design drugs to interact with these receptors.”

“To provide direct evidence for binding of the molecule at different pockets of the receptor, we have developed a new assay, which enables us to measure the binding specifically at the extracellular and the intracellular binding site, providing a unique tool for site-specific discovery”, says Dr. Dorothee Weikert.

“TAS2R receptors do much more than just help us taste bitterness,” the scientists Lior Peri and Dr. Matzov said. “They are found in many parts of the body and are involved in processes like breathing, digestion, and the immune system. By discovering this new pocket, we’ve opened the door to new ways of designing medications that target these receptors, potentially helping to treat conditions like asthma, obesity, and inflammation.”
The research paper titled “A bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR” is now available at Nature Communications and can be accessed at https://www.nature.com/articles/s41467-024-54157-6 (doi.org/10.1038/s41467-024-54157-6)

Founding
Israel Science Foundation, Deutsche Forschungsgemeinschaft (German Research Foundation), European Research Council.

Researchers
Lior Peri1,8†, Donna Matzov2†, Dominic R. Huxley3†, Alon Rainish1,8, Fabrizio Fierro1,8, Liel Sapir1,8, Tara Pfeiffer4, Lukas Waterloo4, Harald Hübner4, Yoav Peleg6, Peter Gmeiner4,5, Peter J. McCormick3,7, Dorothee Weikert4,5*, Masha Y. Niv1,8*, Moran Shalev-Benami2*

1 The Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.
2 Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
3 Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary, University of London, Charterhouse Square, London, UK.
4 Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany.
5 FAUNeW – Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany.
6 Structural Proteomics Unit (SPU), Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel.
7 Department of Pharmacology and Therapeutics, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK L69 3GE.
8 The Fritz Haber Research Center, and the Harvey M. Kruger Center for Nanoscience & Nanotechnology, Institute of Chemistry, The Hebrew University, Jerusalem 9190401, Israel
Attached files
  • Video of the Taste Receptor CryoEM (Credit: Lior Peri and Donna Matzo)
  • A view of the bitter anti-inflammatory Flufenamic acid (orange) at the TAS2R14 (green) binding pocket. [Figure reproduced from Peri, Matzov, Huxley, et al, 2024.]
Regions: Middle East, Israel
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement